A5059171181- RNA Interference and Gene Delivery
- CAR-T cell therapy research
- Immune cells in cancer
- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Advanced biosensing and bioanalysis techniques
- Traumatic Brain Injury and Neurovascular Disturbances
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- Pluripotent Stem Cells Research
- Extracellular vesicles in disease
- Lipid Membrane Structure and Behavior
- Erythrocyte Function and Pathophysiology
- Pancreatic function and diabetes
- Phagocytosis and Immune Regulation
- Spinal Cord Injury Research
- Neonatal Respiratory Health Research
- Advanced Drug Delivery Systems
- Graphene and Nanomaterials Applications
- Cerebrospinal fluid and hydrocephalus
- Polymer Surface Interaction Studies
- Thermal Regulation in Medicine
- Multiple Sclerosis Research Studies
Harvard University
2019-2024
Harvard–MIT Division of Health Sciences and Technology
2019-2024
Massachusetts Institute of Technology
2019-2024
Abstract Approaches to safely and effectively augment cellular functions without compromising the inherent biological properties of cells, especially through integration biologically labile domains, remain great interest. Here, a versatile strategy assemble active nanocomplexes, including proteins, DNA, mRNA, even viral carriers, on surfaces generate cell‐based hybrid system referred as “Cellnex” is established. This can be used engineer wide range cell types in adoptive transfers,...
Multiple sclerosis (MS) is an incurable autoimmune disease and currently treated by systemic immunosuppressants with off-target side effects. Although aberrant myeloid function often observed in MS plaques the central nervous system (CNS), role of cells therapeutic intervention overlooked. Here, we developed a cell-based strategy to reduce burden experimental encephalomyelitis (EAE), mouse model progressive MS. We monocyte-adhered microparticles ("backpacks") for activating cell phenotype...
Natural killer (NK) cell therapies have emerged as a potential therapeutic approach to various cancers. Their efficacy, however, is limited by their low persistence and anergy. Current approaches sustain NK in vivo include genetic modification, activation via pretreatment, or coadministration of supporting cytokines antibodies. Such exhibit efficacy vivo, part due the reversal effect within immunosuppressive tumor microenvironment off-target toxicity. Here, we report material-based address...
The choroid plexus (ChP) of the brain plays a central role in orchestrating recruitment peripheral leukocytes into nervous system (CNS) through blood-cerebrospinal fluid (BCSF) barrier pathological conditions, thus offering unique niche to diagnose CNS disorders. We explored whether magnetic resonance imaging ChP could be optimized for mild traumatic injury (mTBI). mTBI induces subtle, yet influential, changes and is currently severely underdiagnosed. hypothesized that sufficient alterations...
Abstract Messenger ribonucleic acid (mRNA) has long been touted as a next‐generation therapeutic modality for infectious disease, cancer, and genetic disorders. Lipid nanoparticles (LNPs) provide an elegant delivery strategy mRNA cargo to help realize this potential vaccination. However, systemic exposure seen with traditional LNP formulations can have significant implications on efficacy safety. Efforts mitigate largely focused laborious lipid or redesign. Here, the use of deep...
Abstract Adeno‐associated virus (AAV)‐mediated gene therapy is a promising therapeutic modality for curing many diseases including monogenic diseases. However, limited tissue‐targeting and restricted re‐administration due to the vector immunogenicity largely restrict its potential. Here, using red blood cell (RBC) as carrier vehicle AAV demonstrated improve tissue‐targeted transduction enable re‐administration. Anchoring RBC surface minimally affected infectability toward endothelial cells....
Abstract Adoptive cell therapies are dramatically altering the treatment landscape of cancer. However, solid tumors remains a major unmet need, in part due to limited adoptive infiltration into tumor and immunosuppressive microenvironment. The heterogeneity presence nonresponders also call for development antigen‐independent therapeutic approaches. Myeloid cells offer such an opportunity, given their large microenvironment, as triple negative breast utility is hindered by phenotypic...
Abstract Traumatic brain injury (TBI) is a debilitating disease with no current therapies outside of acute clinical management. While acute, controlled inflammation important for debris clearance and regeneration after injury, chronic, rampant plays significant adverse role in the pathophysiology secondary injury. Immune cell hold unique therapeutic potential modulation, due to their active sensing migration abilities. Macrophages are particularly suited this task, given macrophages...
Abstract Cancer therapy is increasingly shifting toward targeting the tumor immune microenvironment and influencing populations of infiltrating lymphocytes. Breast cancer presents a unique challenge as tumors triple‐negative breast subtype employ multitude immunosilencing mechanisms that promote evasion rapid growth. Treatment with chemotherapeutics has been shown to induce underlying immunostimulatory responses can be further amplified addition immune‐modulating agents. Here, we investigate...
B cells, despite their several unique functionalities, remain largely untapped for use as an adoptive cell therapy and are limited to in vitro antibody production. cells can be easily sourced, they possess excellent lymphoid-homing capabilities, act antigen-presenting (APCs), offering alternative dendritic (DCs), which have shown efficacy the clinical setting. Soluble factors such IL-4 anti-CD40 enhance activation, survival, capabilities of cells; however, it is difficult attain sufficiently...
Liposome-based drug delivery systems have allowed for better tolerability and longer circulation times but are often optimized a single agent due to the inherent difficulty of co-encapsulating two drugs with differing chemical profiles. Here, we design test prodrug based on ribosylated nucleoside form 5-fluorouracil, 5-fluorouridine (5FUR), final purpose co-encapsulation doxorubicin (DOX) in liposomes. To improve loading 5FUR, developed 5FUR prodrugs that involved conjugation either one or...